Black Diamond Therapeutics

Founded 2016 · CIK 0001701541 · Biotech · Public

small molecule drugs targeting allosteric sites on cancer-associated proteins

blackdiamondtherapeutics.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$140M
4 Form D · Dec 2019
82 months since last filing
Contracts
—
No federal contracts on record
Patents
40
4 granted · 36 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$7,101,210
Private capital raisedForm D · SEC$5,000,000
Private capital raisedForm D · SEC$42,499,973
Private capital raisedForm D · SEC$84,999,941
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2796Enable Therapeutics LLC——
2797RGENE, INC.——
2798Immunocore Holdings plc—$140M
2799Black Diamond Therapeutics—$140M
2800VYNE Therapeutics Inc.—$139M
2801Silverback Therapeutics—$139M
2802VANQUA BIO, INC.—$136M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 13 related persons
  • Ali BehbahaniDirector
  • Brad BolzonDirector
  • Bradley BolzonDirector
  • Elizabeth BuckExecutive Officer
  • David EpsteinDirector · Executive Officer
  • Brent Hatzis-SchochExecutive Officer
  • Samarth KulkarniDirector
  • Thomas LeggettExecutive Officer
  • Alexander MaywegDirector
  • Garry MenzelDirector
  • Fang NiExecutive Officer
  • Christopher RobertsExecutive Officer
  • Rajeev ShahDirector

Patents

USPTO · 4 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.